- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04967716
Genetics of Charcot-Marie-Tooth Dystrophy and Related Diseases
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
[Background] Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of the most common hereditary peripheral neuropathy, with a prevalence of about 1/2500-4000. The inheritance mode can be autosomal dominant inheritance, autosomal recessive inheritance, X-linked dominant inheritance and X-linked recessive inheritance. The typical clinical manifestations are progressive, length-dependent weakness and atrophy of the distal limbs, accompanied by hypoesthesia and weakened tendon reflexes. But the generalized peroneal muscular atrophy also includes hereditary motor neuropathy and hereditary sensory neuropathy, which represents the evolution of a disease spectrum from motor nerve to motor sensory nerve and sensory nerve, collectively referred to as CMT and its related diseases. CMT can be divided into demyelinating type (CMT1), axonal type (CMT2) and intermediate type. There are more than 80 kinds of genes discovered so far, and genetic diagnosis plays a vital role in the treatment of peroneal muscular atrophy and genetic counseling.
[Purpose]
- To clarify the gene lineage distribution of CMT genes in CMT patients in my country, draw a frequency map of CMT gene distribution, and assist in determining the genetic diagnosis strategy of CMT diseases;
- Discover new mutations and newly published types of known genes, and perform gene-phenotype correlation analysis
- Perform whole-exome sequencing on some families that have not been clearly diagnosed to find new pathogenic genes or related genes of CMT, so as to enrich the genetic and clinical types of CMT.
[Design] This is a cross-sectional study. All patients will be collected for clinical and electrophysiological data. Patients and families who meet the enrollment criteria will be tested for blood tests. The inspection strategies are as follows: (1) Use MLPA method for PMP22 gene Duplicate or deletion mutation check (charge); (2)) Use high-throughput sequencing method to detect the currently known gene panel (gene panel) (charge); (3) Check the process (1) and (2) Some patients and families whose disease-causing genes have not been detected by the inspection methods are tested by whole-exome sequencing (scientific research, free of charge).
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiekontakt
- Navn: Xiaoxuan Liu
- Telefonnummer: 13910982101
- E-mail: zhangys0317@126.com
Undersøgelse Kontakt Backup
- Navn: Xiaoxuan Liu
- E-mail: zhangys0317@126.com
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Peking University Third Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Meet the clinical diagnostic criteria of peroneal muscular atrophy; Sign informed consent
Exclusion Criteria:
- Those who have recently received blood transfusion treatment will not be able to collect blood samples.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Peroneal muscular atrophy
Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity.
It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886.
The prevalence is about 1/2500-4000.
It is the most common hereditary peripheral neuropathy.
Inheritance includes all forms of Mendelian inheritance.
The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
|
Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation.
No fasting is required before blood draw, and there is no time limit.
Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital.
The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
allele frequency of CMT genes
Tidsramme: 1 month
|
Observed values of allele frequency of CMT genes
|
1 month
|
|
genotype frequency of CMT genes
Tidsramme: 1 month
|
Observed values genotype frequency of CMT genes
|
1 month
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Xiaoxuan Liu, Peking University Third Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Neurologiske manifestationer
- Medfødte abnormiteter
- Genetiske sygdomme, medfødte
- Neuromuskulære sygdomme
- Neurodegenerative sygdomme
- Sygdomme i det perifere nervesystem
- Neuromuskulære manifestationer
- Patologiske Tilstande, Anatomiske
- Heredodegenerative lidelser, nervesystem
- Atrofi
- Misdannelser i nervesystemet
- Polyneuropatier
- Muskelatrofi
- Nervekompressionssyndromer
- Charcot-Marie-Tooth sygdom
- Arvelig sensorisk og motorisk neuropati
Andre undersøgelses-id-numre
- M2018206
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .